全文获取类型
| 收费全文 | 9311篇 |
| 免费 | 782篇 |
| 国内免费 | 141篇 |
专业分类
| 耳鼻咽喉 | 103篇 |
| 儿科学 | 188篇 |
| 妇产科学 | 398篇 |
| 基础医学 | 1196篇 |
| 口腔科学 | 194篇 |
| 临床医学 | 952篇 |
| 内科学 | 1882篇 |
| 皮肤病学 | 137篇 |
| 神经病学 | 638篇 |
| 特种医学 | 277篇 |
| 外科学 | 1389篇 |
| 综合类 | 338篇 |
| 现状与发展 | 1篇 |
| 一般理论 | 2篇 |
| 预防医学 | 449篇 |
| 眼科学 | 191篇 |
| 药学 | 935篇 |
| 4篇 | |
| 中国医学 | 198篇 |
| 肿瘤学 | 762篇 |
出版年
| 2023年 | 86篇 |
| 2022年 | 70篇 |
| 2021年 | 257篇 |
| 2020年 | 187篇 |
| 2019年 | 285篇 |
| 2018年 | 319篇 |
| 2017年 | 224篇 |
| 2016年 | 207篇 |
| 2015年 | 324篇 |
| 2014年 | 390篇 |
| 2013年 | 523篇 |
| 2012年 | 699篇 |
| 2011年 | 799篇 |
| 2010年 | 484篇 |
| 2009年 | 390篇 |
| 2008年 | 572篇 |
| 2007年 | 515篇 |
| 2006年 | 517篇 |
| 2005年 | 491篇 |
| 2004年 | 441篇 |
| 2003年 | 358篇 |
| 2002年 | 320篇 |
| 2001年 | 245篇 |
| 2000年 | 202篇 |
| 1999年 | 172篇 |
| 1998年 | 57篇 |
| 1997年 | 48篇 |
| 1996年 | 31篇 |
| 1995年 | 62篇 |
| 1994年 | 47篇 |
| 1993年 | 48篇 |
| 1992年 | 122篇 |
| 1991年 | 94篇 |
| 1990年 | 86篇 |
| 1989年 | 52篇 |
| 1988年 | 54篇 |
| 1987年 | 63篇 |
| 1986年 | 30篇 |
| 1985年 | 36篇 |
| 1984年 | 44篇 |
| 1983年 | 26篇 |
| 1982年 | 25篇 |
| 1981年 | 17篇 |
| 1980年 | 17篇 |
| 1979年 | 24篇 |
| 1978年 | 16篇 |
| 1976年 | 17篇 |
| 1975年 | 18篇 |
| 1973年 | 16篇 |
| 1972年 | 17篇 |
排序方式： 共有10000条查询结果，搜索用时 15 毫秒
1.
Qiangsheng He Chongfei Huang Xiwen Qin Yuanyuan Yu Di Tang Junjie Huang Zi Chong Kuo Yuyao Ling Deli Mao Bin Xia Wenjing Li Kuiqing Lu Man Yang Yulong He Wenbo Meng Jinqiu Yuan Yihang Pan 《International journal of cancer. Journal international du cancer》2023,153(5):942-949
Recent epidemiological studies suggested that proton pump inhibitor (PPI) use was associated with an increased risk of biliary tract cancer (BTC), however, confounders were not adequately controlled. Our study aimed to evaluate PPI use and subsequent risk of BTC and its subtypes in three well-established cohorts. We conducted a pooled analysis of the subjects free of cancers in UK Biobank (n = 463 643), Nurses' Health Study (NHS, n = 80 235) and NHS II (n = 95 869). Propensity score weighted Cox models were used to estimate marginal HRs of PPIs use on BTC risk, accounting for potential confounders. We documented 284 BTC cases in UK Biobank (median follow-up: 7.6 years), and 91 cases in NHS and NHS II cohorts (median follow-up: 15.8 years). In UK biobank, PPI users had a 96% higher risk of BTC compared to nonusers in crude model (HR 1.96, 95% CI 1.44-2.66), but the effect was attenuated to null after adjusting for potential confounders (HR 0.95, 95% CI 0.60-1.49). PPI use was not associated with risk of BTC in the pooled analysis of three cohorts (HR 0.93, 95% CI 0.60-1.43). We also observed no associations between PPI use with risk of intrahepatic (HR 1.00, 95% CI 0.49-2.04), extrahepatic bile duct (HR 1.09, 95% CI 0.52-2.27) and gallbladder cancers (HR 0.66, 95% CI 0.26-1.66) in UK Biobank. In summary, regular use of PPIs was not associated with the risk of BTC and its subtypes. 相似文献
2.
Lin Shu-I. Liao Feng-Ching Chiou Wei-Ru Lin Po-Lin Kuo Jen-Yuan Tsai Cheng-Ting Lee Ying-Hsiang 《Journal of interventional cardiac electrophysiology》2022,63(2):229-230
Journal of Interventional Cardiac Electrophysiology - 相似文献
3.
Dongbing Lai Emma C. Johnson Sarah Colbert Gayathri Pandey Grace Chan Lance Bauer Meredith W. Francis Victor Hesselbrock Chella Kamarajan John Kramer Weipeng Kuang Sally Kuo Samuel Kuperman Yunlong Liu Vivia McCutcheon Zhiping Pang Martin H. Plawecki Marc Schuckit Jay Tischfield Leah Wetherill Yong Zang Howard J. Edenberg Bernice Porjesz Arpana Agrawal Tatiana Foroud 《Alcoholism, clinical and experimental research》2022,46(3):374-383
4.
5.
Denise Lee Marcella D. Walker Hsin Yi Chen John A. Chabot James A. Lee Jennifer H. Kuo 《Surgery》2019,165(1):107-113
Background
Bone mineral density (BMD) has been found to improve after parathyroidectomy (PTX) in patients with primary hyperparathyroidism. There are few data on the effect of PTX on BMD in normocalcemic and normohormonal primary hyperparathyroidism.Methods
A retrospective analysis of 92 primary hyperparathyroidism patients who underwent PTX between 2004 and 2012 with pre- and post-PTX dual-energy x-ray absorptiometry was performed. Within-person changes in BMD pre- and post-PTX were analyzed using log linear mixed models, stratified by biochemical status.Results
Bone mineral density increased post-PTX in the whole cohort at the lumbar spine (+2.5%), femoral neck (+2.1%), and total hip (+1.9%) and decreased at the one-third radius (–0.9%). On comparison of BMD changes by profile, BMD increased in those with the typical profile at the lumbar spine (3.2%), femoral neck (2.9%), and total hip (2.9%) but declined at the one-third radius (–1.5%). In contrast, BMD improved only at the femoral neck (4.3%) in the normohormonal group and did not change at any site in the normocalcemic group. The typical group had a greater increase in BMD over time at the femoral neck and total hip compared with normocalcemic patients.Conclusion
Our results indicate that the skeletal benefit of PTX was attenuated in normocalcemic and normohormonal patients, suggesting that skeletal changes after PTX may depend on biochemical profile. 相似文献6.
7.
8.
Yasmine Assadipour Hui Zhou Eric J. Kuo Philip I. Haigh Annette L. Adams Michael W. Yeh 《Surgery》2019,165(1):99-104
Background
Patients with primary hyperparathyroidism are at risk for skeletal and renal end-organ damage.Methods
We studied patients with biochemically confirmed primary hyperparathyroidism from 1995–2014 and quantified the frequency of osteoporosis, nephrolithiasis, hypercalciuria, and decrease in renal function.Results
The cohort comprised 9,485 patients. In total, 3,303 (35%) had preexisting end-organ effects (osteoporosis, 24%; nephrolithiasis, 10%; hypercalciuria, 5%). Of 6,182 remaining patients, 1,769 (29%) exhibited progression to 1 or more end-organ effects over a median 3.7 years. Among patients with classic primary hyperparathyroidism (calcium and parathyroid hormone increased), progression was unrelated to the degree of hypercalcemia (calcium >11.5 mg/dL, hazard ratio 1.03, 95% confidence interval 0.85–1.25; 11.1–11.5 mg/dL, HR 1.07, 95% confidence interval 0.93–1.23; 10.5–11.0 mg/dL?=?reference). Patients with nonclassic primary hyperparathyroidism (calcium increased, parathyroid hormone 40–65 pg/mL) had a lesser risk of progression (calcium >11.5 mg/dL, hazard ratio 0.68, 95% confidence interval 0.50–0.94; 11.1–11.5 mg/dL, hazard ratio 0.68, 95% confidence interval 0.56–0.82; 10.5–11.0 mg/dL, hazard ratio 0.66, 95% confidence interval 0.59–0.74). End-organ damage developed before or within 5 years of diagnosis for 62% of patients.Conclusion
End-organ manifestations of primary hyperparathyroidism develop before biochemical diagnosis or within 5 years in most patients. End-organ damage occurred more frequently in patients with classic primary hyperparathyroidism versus nonclassic primary hyperparathyroidism, regardless of severity of hypercalcemia. 相似文献9.
10.